Company Overview
About Insulet Corporation
Insulet Corporation is an Acton, Massachusetts-based medical device company — publicly traded on the NASDAQ (NASDAQ: PODD) as an S&P 500 Health Care component — developing, manufacturing, and commercializing the Omnipod insulin delivery system: a tubeless, wearable, waterproof insulin pump patch worn directly on the body without tubing connections to a separate controller, automatically delivering insulin to people with type 1 and type 2 diabetes through approximately 5,000 employees globally. In fiscal year 2024, Insulet reported revenues of $2.18 billion (+21% year-over-year), driven by Omnipod 5 (Omnipod's automated insulin delivery — AID — system integrating with Dexcom CGM and Abbott FreeStyle Libre sensors to automatically adjust insulin delivery based on real-time glucose readings without manual user input), which drove international expansion in Europe and adoption in type 2 diabetes patients who previously used multiple daily injections rather than insulin pumps. CEO Jim Hollingshead has accelerated Omnipod's differentiation through the automated insulin delivery positioning: Omnipod 5's algorithm automatically modulates basal insulin rates every 5 minutes based on continuous glucose monitor readings — reducing A1c levels and time-in-hypoglycemia without requiring the user to manually program correction boluses for most scenarios — transforming diabetes management from active self-management to a background automated process that dramatically improves quality of life for insulin-dependent diabetics.
Business Model & Competitive Advantage
Insulet's tubeless insulin pump model creates competitive advantages through the patient comfort differentiation of Omnipod's patch design versus traditional tubed insulin pumps: conventional insulin pumps (Medtronic MiniMed, Tandem Diabetes t:slim) consist of a hockey-puck-sized pump connected by 24-42 inches of tubing to an infusion set inserted under the skin — requiring the device to be carried in a pocket, attached to clothing, or clipped to a belt, limiting wearability during bathing, swimming, and intimacy. Omnipod's tubeless patch (the size of a small bandage, worn directly on the abdomen, arm, or thigh) eliminates the tubing limitation and the associated social stigma of visible medical devices — enabling discreet insulin delivery that improves therapy adoption and adherence among adults and adolescents who avoided traditional pumps due to tubing inconvenience. The Omnipod consumable business model (patients use a new Pod every 3 days at $30-40 per Pod, generating $3,000-5,000 per patient annually in recurring Pod revenue independent of insulin cost) creates predictable, recurring revenue that grows as the installed base of Omnipod users expands globally.
Competitive Landscape 2025–2026
In 2025, Insulet competes in insulin delivery systems and automated insulin delivery against Medtronic (NYSE: MDT, MiniMed 780G AID system), Tandem Diabetes Care (NASDAQ: TNDM, t:slim X2 with Control-IQ algorithm), and Abbott Laboratories (NYSE: ABT, FreeStyle Libre CGM — partnering with Insulet but also competing for diabetes management market share) for insulin pump market share, type 2 diabetes pump adoption, and AID system clinical outcomes positioning. The type 2 diabetes market expansion represents Insulet's largest growth opportunity: the 7-8 million insulin-treated type 2 diabetics in the US who use multiple daily injections represent a conversion opportunity for Omnipod's simplified wearable delivery — requiring clinical evidence that AID benefits in type 2 patients justify premium device cost versus insulin pen injections. Insulet's international expansion (Europe, Japan, Australia) has driven 55%+ of revenue outside the US, with European reimbursement coverage for Omnipod across major health systems (NHS in UK, German GKV, French CPAM) providing structural market access. The 2025 strategy focuses on Omnipod 5 AID international reimbursement expansion, type 2 diabetes clinical outcomes data generation, and next-generation Omnipod platform development (smaller form factor, longer wear time).
The Insulet Corporation Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Insulet Corporation's journey
Leadership Team
Meet the leaders behind Insulet Corporation
Ashley McEvoy
Ashley McEvoy joined Insulet as President and CEO in April 2025, bringing extensive MedTech leadership experience from Johnson & Johnson where she served for over 27 years, most recently as EVP and Worldwide Chair of Johnson & Johnson MedTech from 1996 to 2023.
Jim Hollingshead
Jim Hollingshead served as President and CEO until April 2025, leading Insulet through a period of significant growth and the successful launch of Omnipod 5 automated insulin delivery system.
Shacey Petrovic
Shacey Petrovic previously served as CEO and continues to contribute to Insulet's strategic direction as a board member, having led the company through major product innovations and market expansion.
Flavia Pease
Flavia Pease has served on Insulet's Board of Directors since January 2024. She currently serves as Corporate EVP and CFO at Charles River Laboratories since 2022, bringing extensive financial and operational expertise.
Key Differentiators
Market Leader
Insulet Corporation is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $2.18B in revenue, Insulet Corporation operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Insulet Corporation with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Insulet Corporation? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Insulet Corporation Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Insulet Corporation vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →